Allogene Therapeutics, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2022-09-30 was 0.00 shares.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2021-09-30 was 0.00 shares.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2019-09-30 was 200.62K shares.
- Allogene Therapeutics, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2018 was 5.02M shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2022-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | |
| 2021-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-02 | |
| 2019-09-30 | 200.62K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-05 | |
| 2018-12-31 | 5.02M shares 10-K · filed 2019-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Prime Medicine, Inc. (PRME) | United States | $0.557B | -3.54 |
| Aura Biosciences, Inc. (AURA) | United States | $0.639B | -5.61 |
| Autolus Therapeutics plc (AUTL) | $0.506B | -1.52 | |
| Entera Bio Ltd. (ENTX) | $0.485B | ||
| REGENXBIO Inc. (RGNX) | United States | $0.477B | -3.30 |
| Tectonic Therapeutic, Inc. (TECX) | United States | $0.469B | -7.68 |
| Eikon Therapeutics, Inc. (EIKN) | United States | $0.446B | |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |